
Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.

Asimov provides scientists and manufacturers tools that simplify designing and manufacturing biologic drugs and gene therapies. The company combines mammalian synthetic biology with computer-aided design and machine learning to program living cells and optimize therapeutic candidates. Its platform uses AI-driven predictive models and CAD-style design workflows to accelerate biological design cycles for research teams, biotechs, and contract developers. Asimov operates in the B2B life sciences software and tools market focused on next-generation therapeutics.
Founded: 2017
Headquarters: Boston
Focus: Cells-to-software synthetic biology platform for designing and manufacturing biologics and cell/gene therapies
Product highlights: CHO Edge, LV Edge, AAV Edge, Kernel (genetic design software)
Funding: $205,000,000 total (latest listed: Series B on 2023-01-05)
Synthetic biology and biomanufacturing for next-generation therapeutics (biologics, cell and gene therapies).
2017
Biotechnology Research
$4.7M
Reported seed funding amount per press coverage.
“Backed by institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, Fidelity Management & Research Company, Casdin Capital, DCVC, AME Cloud Ventures, KdT Ventures, and Pillar VC.”
| Company |
|---|
Our mission at Asimov is to advance humanity's ability to design living systems, enabling biotechnologies with outsized benefit to society. We've built a mammalian synthetic biology platform – from cells to software – to enable the design and manufacture of next-generation therapeutics.
We are seeking a Head of Cell Line Development (CLD) to lead Asimov’s biologics CLD team and help push the boundaries of biologics manufacturing. The successful candidate will be responsible for managing direct reports and lab activities in support of the generation and characterization of cell lines expressing the highest quantity and quality of protein therapeutics. We have experienced rapid growth in both our project portfolio and CLD team, and we expect that growth trajectory to continue for the foreseeable future. This role will be central to scaling capabilities, workflows, and leadership structures accordingly.
This role requires a strategic leader with a deep technical foundation in biologics cell line development and a proven track record of growing and managing high-performing teams. Working closely with Asimov’s synthetic biology, process development, computational modeling, and software teams, this role will shape Asimov’s CLD vision and contribute as a thought leader to advance the state of the art in biologics cell line development. The role will also partner with commercial, program management, and technical teams to support customer-facing communications, including scientific discussions with prospective clients and collaborators. This is a unique opportunity to work at a nimble, forward-thinking synthetic biology company.
About The Role
About You
We're fueled by a vision to transform biological engineering into a fully-fledged engineering discipline. Should you join our team, you will grow with a constantly evolving organization and push the frontiers of synthetic biology. Company culture is key to Asimov, and ours is a culture of recombination; we believe that our mission can only be achieved by bringing together a diverse team with a mixture of backgrounds and perspectives.
Compensation Range: $220K - $280K